Cerus Corp. (CERS) Tuesday announced positive results for the phase 3 clinical trial of the pathogen-reduced INTERCEPT blood system for red blood cells in cardiovascular surgery patients.
The company said the trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury compared to conventional red blood cells. Acute kidney injury is a sensitive transfusion efficacy indicator of RBC tissue oxygen delivery.
The safety endpoint is being explored in the ongoing RedeS Phase 3 clinical trial of INTERCEPT RBCs.
Cerus said it anticipates initiating a modular PMA application to FDA in the second half of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.